About ORIC Pharmaceuticals, Inc.
https://www.oricpharma.comORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.
CEO
Jacob M. Chacko
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 110
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Citigroup
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Wedbush
Outperform
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
NEXTECH INVEST, LTD.
Shares:7.16M
Value:$80.58M
ECOR1 CAPITAL, LLC
Shares:6.73M
Value:$75.69M
VR ADVISER, LLC
Shares:6.6M
Value:$74.21M
Summary
Showing Top 3 of 162
About ORIC Pharmaceuticals, Inc.
https://www.oricpharma.comORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $36.67M ▼ | $-32.59M ▲ | 0% | $-0.33 ▲ | $-32.3M ▲ |
| Q2-2025 | $0 | $39.06M ▲ | $-36.35M ▼ | 0% | $-0.47 ▼ | $-38.75M ▼ |
| Q1-2025 | $0 | $32.72M ▼ | $-30.02M ▲ | 0% | $-0.42 ▲ | $-32.42M ▲ |
| Q4-2024 | $0 | $39.27M ▲ | $-36.31M ▼ | 0% | $-0.51 ▼ | $-36M ▲ |
| Q3-2024 | $0 | $38.32M | $-34.57M | 0% | $-0.49 | $-38.05M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $287.14M ▲ | $431.19M ▲ | $24.27M ▲ | $406.92M ▲ |
| Q2-2025 | $282.51M ▲ | $346.86M ▲ | $22.86M ▼ | $324M ▲ |
| Q1-2025 | $203.72M ▼ | $242.86M ▼ | $23.12M ▼ | $219.74M ▼ |
| Q4-2024 | $255.96M ▼ | $274.14M ▼ | $31.02M ▲ | $243.12M ▼ |
| Q3-2024 | $272.37M | $302.07M | $28.08M | $273.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-32.59M ▲ | $-25.11M ▲ | $-110.53M ▼ | $109.45M ▼ | $-26.2M ▼ | $-25.15M ▲ |
| Q2-2025 | $-36.35M ▼ | $-30.84M ▲ | $-76.93M ▼ | $134.3M ▲ | $26.53M ▲ | $-30.91M ▲ |
| Q1-2025 | $-30.02M ▲ | $-32.77M ▼ | $22.45M ▼ | $253K ▼ | $-10.07M ▼ | $-33.16M ▼ |
| Q4-2024 | $-36.31M ▼ | $-28.05M ▲ | $42.66M ▲ | $575K ▲ | $15.18M ▲ | $-28.27M ▲ |
| Q3-2024 | $-34.57M | $-28.8M | $23.07M | $126K | $-5.6M | $-29.21M |
CEO
Jacob M. Chacko
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 110
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Citigroup
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Wedbush
Outperform
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
NEXTECH INVEST, LTD.
Shares:7.16M
Value:$80.58M
ECOR1 CAPITAL, LLC
Shares:6.73M
Value:$75.69M
VR ADVISER, LLC
Shares:6.6M
Value:$74.21M
Summary
Showing Top 3 of 162